Related Experiment Video

Updated: Aug 11, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

[Integral treatment of congenital Chagas disease: the Bolivian experience ]

Eduardo Suárez1, Cristina Alonso-Vega, Faustino Torrico

  • 1Centro Universitario de Medicina Tropical, Facultad de Medicina, Universidad Mayor de San Simon (U.M.S.S.), Avenida Aniceto Arce 371, casilla 3023, Cochabamba, Bolivia. esuarezba@yahoo.com

Revista Da Sociedade Brasileira De Medicina Tropical
|February 18, 2006
PubMed

Insights

Benznidazole treatment in newborns and nurslings showed nearly 100% effectiveness when administered correctly. This study found no significant adverse effects, highlighting benznidazole

Area of Science:

  • Pediatric infectious diseases
  • Pharmacology and therapeutics

Background:

  • Chagas disease (American trypanosomiasis) is a significant public health concern in endemic regions.
  • Early diagnosis and treatment in newborns and nurslings are crucial for preventing disease progression and chronic complications.

Purpose of the Study:

  • To evaluate the efficacy and safety of benznidazole treatment in newborns and nurslings.
  • To assess the importance of integral treatment and family guidance for pediatric Chagas disease management.

Main Methods:

  • Retrospective analysis of treatment data for newborns and nurslings.
  • Study conducted at Hospital Materno Infantil Germán Urquidi, Cochabamba, Bolivia (1999-2002).
  • Monitoring for treatment response, adverse effects, and biochemical alterations.

Main Results:

  • Benznidazole treatment achieved a response rate close to 100% when correctly administered.
  • No adverse effects were reported during the treatment period.
  • Detected biochemical alterations were not clinically significant.

Conclusions:

  • Benznidazole is a highly effective and safe treatment for Chagas disease in newborns and nurslings.
  • Integral management, including family education, is vital for successful treatment outcomes.
  • Early intervention with benznidazole can prevent long-term sequelae of Chagas disease in pediatric populations.

More Related Videos

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates13:55

Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates

Published on: January 27, 2019

Related Concept Videos

American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...